We are live on ! Find out more
BCRX icon

BioCryst Pharmaceuticals
BCRX

236 hedge funds and large institutions have $1.23B invested in BioCryst Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 99 increasing their positions, 57 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

280% more call options, than puts

Call options by funds: $18.3M | Put options by funds: $4.82M

74% more repeat investments, than reductions

Existing positions increased: 99 | Existing positions reduced: 57

1.78% more ownership

Funds ownership: 90.36% → 92.14% (+1.8%)

2% less funds holding

Funds holding: 241 → 236 (-5)

13% less first-time investments, than exits

New positions opened: 26 | Existing positions closed: 30

14% less capital invested

Capital invested by funds: $1.42B → $1.23B (-$196M)

25% less funds holding in top 10

Funds holding in top 10: 8 → 6 (-2)

Holders
236
Holders Change
-5
Holders Change %
-2.07%
% of All Funds
3.71%
Holding in Top 10
6
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-25%
% of All Funds
0.09%
New
26
Increased
99
Reduced
57
Closed
30
Calls
$18.3M
Puts
$4.82M
Net Calls
+$13.5M
Net Calls Change
-$2.37M

Top Buyers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$31.7M
2
RHJA
Rice Hall James & Associates
California
+$15M
3
KCM
Kynam Capital Management
New Jersey
+$14.8M
4
ACA
Avoro Capital Advisors
New York
+$13.1M
5
PM
Prosight Management
Texas
+$11.4M

Top Sellers

1
Artisan Partners
Artisan Partners
Wisconsin
-$23.7M
2
Bank of America
Bank of America
North Carolina
-$18.1M
3
PHS
PFM Health Sciences
California
-$18M
4
EP
Eversept Partners
New York
-$17.2M
5
DM
Deerfield Management
New York
-$11.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$109M +$5.38M +670,905 +5%
Vanguard Group
2
Vanguard Group
Pennsylvania
$106M +$2.12M +263,936 +2%
BBA
3
Baker Bros. Advisors
New York
$89.5M – – –
State Street
4
State Street
Massachusetts
$86.3M +$7.02M +874,346 +8%
ACA
5
Avoro Capital Advisors
New York
$84.9M +$13.1M +1,635,000 +16%
Assenagon Asset Management
6
Assenagon Asset Management
Luxembourg
$37.5M +$2.93M +365,077 +7%
Millennium Management
7
Millennium Management
New York
$37.3M +$6.94M +864,691 +19%
PAMS
8
Pictet Asset Management (Switzerland)
Switzerland
$37.2M -$2.66M -331,836 -6%
Fisher Asset Management
9
Fisher Asset Management
Washington
$30.4M +$250K +31,157 +0.7%
Point72 Asset Management
10
Point72 Asset Management
Connecticut
$28.2M +$31.7M +3,951,200 +7,385%
RM
11
RP Management
New York
$27.1M – – –
Geode Capital Management
12
Geode Capital Management
Massachusetts
$27M +$1.44M +178,999 +5%
Fidelity Investments
13
Fidelity Investments
Massachusetts
$20.8M -$1.75M -217,712 -7%
KCM
14
Kynam Capital Management
New Jersey
$20.1M +$14.8M +1,848,197 +185%
B
15
Braidwell
Connecticut
$19.7M +$6.79M +846,746 +44%
GKIM
16
GW&K Investment Management
Massachusetts
$18.3M -$45.7K -5,689 -0.2%
PM
17
Prosight Management
Texas
$17.6M +$11.4M +1,425,407 +133%
RSCM
18
Rock Springs Capital Management
Maryland
$17.6M +$1.31M +163,108 +7%
TCM
19
Tang Capital Management
California
$17.2M +$6.82M +850,000 +53%
BNP Paribas Asset Management
20
BNP Paribas Asset Management
France
$17M -$3.83M -477,549 -17%
EP
21
Eversept Partners
New York
$16.7M -$17.2M -2,148,611 -48%
Two Sigma Advisers
22
Two Sigma Advisers
New York
$15M -$522K -65,100 -3%
SBH
23
Segall Bryant & Hamill
Illinois
$14.3M +$1.6M +199,834 +11%
EAM
24
Eventide Asset Management
Massachusetts
$13.9M +$6.96M +867,111 +79%
RHJA
25
Rice Hall James & Associates
California
$13.2M +$15M +1,872,964 New
1
2 3 4 5

BCRX Hedge Fund Activity: Q2 2023 in Review

236 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q2 2023, worth a combined $1.23B — down 14% from $1.42B a quarter earlier.

Sellers outnumbered buyers: 30 funds closed out of BCRX and 26 opened new positions — a net loss of 4 holders — while 57 trimmed existing stakes and 99 added.

The largest buyer was Point72 Asset Management, adding an estimated $31.7M. The largest seller was Artisan Partners, exiting entirely with an estimated $23.7M sold.

  • 236 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q2 2023, down from 241 in Q1 2023.
  • Funds reported $1.23B of BioCryst Pharmaceuticals stock for Q2 2023, down 14% quarter-over-quarter.
  • 26 funds opened new BioCryst Pharmaceuticals positions in Q2 2023 and 30 closed out, a net change of -4 holders.
  • The largest BioCryst Pharmaceuticals buyer in Q2 2023 was Point72 Asset Management, an estimated $31.7M added.
  • The largest BioCryst Pharmaceuticals seller in Q2 2023 was Artisan Partners, an estimated $23.7M sold.

Based on aggregated 13F filings for Q2 2023.